FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Michael Duffy

Research Profile

Disorders

Chemicals & Drugs

Procedures

Enzyme-Linked Immunosorbent Assay

Physiology

Concepts & Ideas

Survival Rate

Co-author Network

Publications

TOP 3
Patricia McGowan; M Mullooly; Norma O'Donovan; A Pierce; S Sukor; F Caiazza; John Crown; S F Madden; A A Maguire; E W McDermott; Michael J Duffy
ADAM-17: a novel therapeutic target for triple negative breast cancer.
Michael J Duffy
Tumor markers in clinical practice: a review focusing on common solid cancers.
Brigid C Browne; John Crown; Michael J Duffy; Alex J Eustace; John Kennedy; Susan Kennedy; Annemarie Larkin; Stephen Madden; Thamir Mahgoub; Martina S J McDermott; Neil A O'Brien; Kasper Pedersen; Francesco Sclafani; Josephine Ballot; Norma O'Donovan
Evaluation of IGF1R and phosphorylated IGF1R as targets in HER2-positive breast cancer cell lines and tumours.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Michael Duffy (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Patricia McGowan; M Mullooly; Norma O'Donovan; A Pierce; S Sukor; F Caiazza; John Crown; S F Madden; A A Maguire; E W McDermott; Michael J Duffy
ADAM-17: a novel therapeutic target for triple negative breast cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2013;24(2):362-9.
2013: Michael J Duffy
Tumor markers in clinical practice: a review focusing on common solid cancers.
Medical principles and practice : international journal of the Kuwait University, Health Science Centre 2013;22(1):4-11.
2012: Brigid C Browne; John Crown; Michael J Duffy; Alex J Eustace; John Kennedy; Susan Kennedy; Annemarie Larkin; Stephen Madden; Thamir Mahgoub; Martina S J McDermott; Neil A O'Brien; Kasper Pedersen; Francesco Sclafani; Josephine Ballot; Norma O'Donovan
Evaluation of IGF1R and phosphorylated IGF1R as targets in HER2-positive breast cancer cell lines and tumours.
Breast cancer research and treatment 2012;136(3):717-27.
2012: D M Collins; Michael J Duffy; P M McGowan; Norma O'Donovan; F O'Sullivan; John Crown
Trastuzumab induces antibody-dependent cell-mediated cytotoxicity (ADCC) in HER-2-non-amplified breast cancer cell lines.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2012;23(7):1788-95.
2011: D Tryfonopoulos; S Walsh; D M Collins; B Corkery; John Crown; D Evoy; L Flanagan; E W McDermott; Norma O'Donovan; A Pierce; C Quinn; Michael J Duffy
Src: a potential target for the treatment of triple-negative breast cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2011;22(10):2234-40.
2011: Catharine M Sturgeon; Michael J Duffy; Graeme Walker
The National Institute for Health and Clinical Excellence (NICE) guidelines for early detection of ovarian cancer: the pivotal role of the clinical laboratory.
Annals of clinical biochemistry 2011;48(Pt 4):295-9.
2011: Michael J Duffy
Prostate-specific antigen: does the current evidence support its use in prostate cancer screening?
Annals of clinical biochemistry 2011;48(Pt 4):310-6.
2011: Eadaoin McKiernan; Enda W McDermott; Dennis Evoy; John Crown; Michael J Duffy
The role of S100 genes in breast cancer progression.
Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine 2011;32(3):441-50.
2011: Michael J Duffy; Norma O'Donovan; John Crown
Use of molecular markers for predicting therapy response in cancer patients.
Cancer treatment reviews 2011;37(2):151-9.
2011: Michael J Duffy; John Crown; Maeve Mullooly; Norma O'Donovan; Aisling Pierce; Sumainizah Sukor; Patricia M McGowan
The ADAMs family of proteases: new biomarkers and therapeutic targets for cancer?
Clinical proteomics 2011;8(1):9.
2011: Michael J Duffy; Leo G M van Rossum; Sietze T van Turenhout; Outi Malminiemi; Catherine Sturgeon; Rolf Lamerz; Andrea Nicolini; Caj Haglund; Lubos Holubec; Callum G Fraser; Stephen P Halloran
Use of faecal markers in screening for colorectal neoplasia: a European group on tumor markers position paper.
International journal of cancer. Journal international du cancer 2011;128(1):3-11.
2011: Brigid Browne; John Crown; N Venkatesan; Michael J Duffy; Martin Clynes; Dennis J Slamon; Norma O'Donovan
Inhibition of IGF1R activity enhances response to trastuzumab in HER-2-positive breast cancer cells.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2011;22(1):68-73.
2010: Michael J Duffy; Denis Evoy; Enda W McDermott
CA 15-3: uses and limitation as a biomarker for breast cancer.
Clinica chimica acta; international journal of clinical chemistry 2010;411(23-24):1869-74.
2010: Aisling Pierce; Radka Saldova; Umi M Abd Hamid; Jodie L Abrahams; Enda W McDermott; Denis Evoy; Michael J Duffy; Pauline M Rudd
Levels of specific glycans significantly distinguish lymph node-positive from lymph node-negative breast cancer patients.
Glycobiology 2010;20(10):1283-8.
2010: Neil A O'Brien; Brigid Browne; Lucy Chow; Yuhua Wang; Charles Ginther; Jane Arboleda; Michael J Duffy; John Crown; Norma O'Donovan; Dennis J Slamon
Activated phosphoinositide 3-kinase/AKT signaling confers resistance to trastuzumab but not lapatinib.
Molecular cancer therapeutics 2010;9(6):1489-502.
2010: Catharine M Sturgeon; Michael J Duffy; Barry R Hofmann; Rolf Lamerz; Herbert A Fritsche; Katja Gaarenstroom; Johannes Bonfrer; Thorsten H Ecke; H Barton Grossman; Peter Hayes; Ralf-Thorsten Hoffmann; Seth P Lerner; Florian Löhe; Johanna Louhimo; Ihor Sawczuk; Kazuhisa Taketa; Eleftherios P Diamandis
National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for use of tumor markers in liver, bladder, cervical, and gastric cancers.
Clinical chemistry 2010;56(6):e1-48.
2010: Thomas Y K Lau; Karen A Power; Sophie Dijon; Isabelle de Gardelle; Susan McDonnell; Michael J Duffy; Stephen R Pennington; William M Gallagher
Prioritization of candidate protein biomarkers from an in vitro model system of breast tumor progression toward clinical verification.
Journal of proteome research 2010;9(3):1450-9.
2010: Michael J Duffy; C Sturgeon; Rolf Lamerz; C Haglund; V L Holubec; R Klapdor; A Nicolini; O Topolcan; V Heinemann
Tumor markers in pancreatic cancer: a European Group on Tumor Markers (EGTM) status report.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2010;21(3):441-7.
2010: Elton Rexhepaj; Karin Jirstrom; Darran P O'Connor; Sallyann L O'Brien; Göran Landberg; Michael J Duffy; Donal J Brennan; William M Gallagher
Validation of cytoplasmic-to-nuclear ratio of survivin as an indicator of improved prognosis in breast cancer.
BMC cancer 2010;10():639.
2009: Brigid Browne; N O'Brien; Michael J Duffy; John Crown; Norma O'Donovan
HER-2 signaling and inhibition in breast cancer.
Current cancer drug targets 2009;9(3):419-38.
2009: Michael J Duffy; Eadaoin McKiernan; Norma O'Donovan; Patricia McGowan
The role of ADAMs in disease pathophysiology.
Clinica chimica acta; international journal of clinical chemistry 2009;403(1-2):31-6.
2009: Fiona Lanigan; Eadaoin McKiernan; Donal J Brennan; Shauna Hegarty; Robert C Millikan; Jean McBryan; Karin Jirstrom; Göran Landberg; Finian Martin; Michael J Duffy; William M Gallagher
Increased claudin-4 expression is associated with poor prognosis and high tumour grade in breast cancer.
International journal of cancer. Journal international du cancer 2009;124(9):2088-97.
2009: Michael J Duffy; R Napieralski; John Martens; P N Span; F Spyratos; F C G J Sweep; N Brunner; J A Foekens; Manfred Schmitt
Methylated genes as new cancer biomarkers.
European journal of cancer (Oxford, England : 1990) 2009;45(3):335-46.
2009: C M Sturgeon; L C Lai; Michael J Duffy
Serum tumour markers: how to order and interpret them.
BMJ (Clinical research ed.) 2009;339():b3527.
2009: G C Markey; R Cullen; P Diggin; A D K Hill; E W Mc Dermott; Niall J O'Higgins; Michael J Duffy
Estrogen receptor-beta mRNA is associated with adverse outcome in patients with breast cancer.
Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine 2009;30(4):171-5.
2008: Catharine M Sturgeon; Michael J Duffy; Ulf-Hakan Stenman; Hans Lilja; Nils Brünner; Daniel W Chan; Richard Babaian; Robert C Bast; Barry Dowell; Francisco J Esteva; Caj Haglund; Nadia Harbeck; Daniel F Hayes; Mads Holten-Andersen; George G Klee; Rolf Lamerz; Leendert H Looijenga; Rafael Molina; Hans Jørgen Nielsen; Harry Rittenhouse; Axel Semjonow; Ie-Ming Shih; Paul Sibley; György Sölétormos; Carsten Stephan; Lori J Sokoll; Barry R Hoffman; Eleftherios P Diamandis
National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers.
Clinical chemistry 2008;54(12):e11-79.
2008: Michael J Duffy; John Crown
A personalized approach to cancer treatment: how biomarkers can help.
Clinical chemistry 2008;54(11):1770-9.
2008: Patricia McGowan; Michael J Duffy
Matrix metalloproteinase expression and outcome in patients with breast cancer: analysis of a published database.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2008;19(9):1566-72.
2008: Patricia McGowan; E McKiernan; F Bolster; B M Ryan; A D K Hill; E W McDermott; D Evoy; Niall O'Higgins; John Crown; Michael J Duffy
ADAM-17 predicts adverse outcome in patients with breast cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2008;19(6):1075-81.
2008: Maryla Krajewska; Shinichi Kitada; Jane N Winter; Daina Variakojis; Alan Lichtenstein; Dayong Zhai; Michael Cuddy; Xianshu Huang; Frederic Luciano; Cheryl H Baker; Hoguen Kim; Eunah Shin; Susan Kennedy; Allen H Olson; Andrzej Badzio; Jacek Jassem; Ivo Meinhold-Heerlein; Michael J Duffy; Aaron D Schimmer; Ming Tsao; Ewan Brown; Anne Sawyers; Michael Andreeff; Dan Mercola; Stan Krajewski; John C Reed
Bcl-B expression in human epithelial and nonepithelial malignancies.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(10):3011-21.
2008: Donal J Brennan; Elton Rexhepaj; Sallyann L O'Brien; Elaine McSherry; Darran P O'Connor; Ailís Fagan; Aedín C Culhane; Desmond G Higgins; Karin Jirstrom; Robert C Millikan; Göran Landberg; Michael J Duffy; Stephen M Hewitt; William M Gallagher
Altered cytoplasmic-to-nuclear ratio of survivin is a prognostic indicator in breast cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(9):2681-9.
2008: Michael J Duffy; Patricia McGowan; W M Gallagher
Cancer invasion and metastasis: changing views.
The Journal of pathology 2008;214(3):283-93.
2008: Elton Rexhepaj; Donal J Brennan; Peter Holloway; Elaine W Kay; Amanda McCann; Göran Landberg; Michael J Duffy; Karin Jirstrom; William M Gallagher
Novel image analysis approach for quantifying expression of nuclear proteins assessed by immunohistochemistry: application to measurement of oestrogen and progesterone receptor levels in breast cancer.
Breast cancer research : BCR 2008;10(5):R89.
2007: Michael J Duffy; Arie Van Dalen; C Haglund; L Hansson; E Holinski-Feder; R Klapdor; Rolf Lamerz; P Peltomaki; C Sturgeon; Ondrej Topolcan
Tumour markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines for clinical use.
European journal of cancer (Oxford, England : 1990) 2007;43(9):1348-60.
2007: Donal J Brennan; Catherine Kelly; Elton Rexhepaj; Peter A Dervan; Michael J Duffy; William M Gallagher
Contribution of DNA and tissue microarray technology to the identification and validation of biomarkers and personalised medicine in breast cancer.
Cancer genomics & proteomics 2007;4(3):121-34.
2007: Michael J Duffy
Role of tumor markers in patients with solid cancers: A critical review.
European journal of internal medicine 2007;18(3):175-84.
2007: Michael J Duffy; Norma O'Donovan; Donal J Brennan; William M Gallagher; Bríd M Ryan
Survivin: a promising tumor biomarker.
Cancer letters 2007;249(1):49-60.
2007: Patricia McGowan; Bríd M Ryan; A D K Hill; Enda McDermott; Niall O'Higgins; Michael J Duffy
ADAM-17 expression in breast cancer correlates with variables of tumor progression.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(8):2335-43.
2007: Sallyann L O'Brien; Ailís Fagan; Edward J P Fox; Robert C Millikan; Aedín C Culhane; Donal J Brennan; Amanda McCann; Shauna Hegarty; Siobhan Moyna; Michael J Duffy; Desmond G Higgins; Karin Jirström; Göran Landberg; William M Gallagher
CENP-F expression is associated with poor prognosis and chromosomal instability in patients with primary breast cancer.
International journal of cancer. Journal international du cancer 2007;120(7):1434-43.
2007: Jane Culleton; Neil O'Brien; Bríd M Ryan; A D K Hill; Enda McDermott; Niall O'Higgins; Michael J Duffy
Lipophilin B: A gene preferentially expressed in breast tissue and upregulated in breast cancer.
International journal of cancer. Journal international du cancer 2007;120(5):1087-92.
2007: Thomas Y K Lau; Darran P O'Connor; Donal J Brennan; Michael J Duffy; Stephen R Pennington; William M Gallagher
Breast cancer proteomics: clinical perspectives.
Expert opinion on biological therapy 2007;7(2):209-19.
2007: Neil O'Brien; Norma O'Donovan; Deirdre Foley; A D K Hill; Enda McDermott; Niall O'Higgins; Michael J Duffy
Use of a panel of novel genes for differentiating breast cancer from non-breast tissues.
Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine 2007;28(6):312-7.
2006: Donal J Brennan; Karin Jirstrom; Asa Kronblad; Robert C Millikan; Göran Landberg; Michael J Duffy; Lisa Rydén; William M Gallagher; Sallyann L O'Brien
CA IX is an independent prognostic marker in premenopausal breast cancer patients with one to three positive lymph nodes and a putative marker of radiation resistance.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(21):6421-31.
2006: B M Ryan; Gottfried E Konecny; S Kahlert; H-J Wang; M Untch; G Meng; Mark D Pegram; K C Podratz; John Crown; Dennis J Slamon; Michael J Duffy
Survivin expression in breast cancer predicts clinical outcome and is associated with HER2, VEGF, urokinase plasminogen activator and PAI-1.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2006;17(4):597-604.
2006: Alexei Y Savinov; Albert G Remacle; Vladislav Golubkov; Maryla Krajewska; Susan Kennedy; Michael J Duffy; Dmitri V Rozanov; Stan Krajewski; Alex Y Strongin
Matrix metalloproteinase 26 proteolysis of the NH2-terminal domain of the estrogen receptor beta correlates with the survival of breast cancer patients.
Cancer research 2006;66(5):2716-24.
2006: Michael J Duffy
Serum tumor markers in breast cancer: are they of clinical value?
Clinical chemistry 2006;52(3):345-51.
2006: Yvonne Buggy; Teresa M Maguire; Enda McDermott; A D K Hill; Niall O'Higgins; Michael J Duffy
Ets2 transcription factor in normal and neoplastic human breast tissue.
European journal of cancer (Oxford, England : 1990) 2006;42(4):485-91.
2006: Michael J Duffy
Estrogen receptors: role in breast cancer.
Critical reviews in clinical laboratory sciences 2006;43(4):325-47.
2005: Rafael Molina; Vivian Barak; Arie Van Dalen; Michael J Duffy; Roland Einarsson; Massimo Gion; Helenka Goike; Rolf Lamerz; Marius Nap; György Sölétormos; Petra Stieber
Tumor markers in breast cancer- European Group on Tumor Markers recommendations.
Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine 2005;26(6):281-93.
2005: Andrew W Roddam; Michael J Duffy; Freddie C Hamdy; Anthony Milford Ward; Julietta Patnick; Chris Price; Janet Rimmer; Cathie Sturgeon; Peter White; Naomi E Allen
Use of prostate-specific antigen (PSA) isoforms for the detection of prostate cancer in men with a PSA level of 2-10 ng/ml: systematic review and meta-analysis.
European urology 2005;48(3):386-99; discussion 398-9.
2005: Maryla Krajewska; Hoguen Kim; Eunah Shin; Susan Kennedy; Michael J Duffy; Yick F Wong; David Marr; Jowita Mikolajczyk; Ahmed Shabaik; Ivo Meinhold-Heerlein; Xianshu Huang; Steven Banares; Hirad Hedayat; John C Reed; Stan Krajewski
Tumor-associated alterations in caspase-14 expression in epithelial malignancies.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(15):5462-71.
2005: Donal J Brennan; Sallyann L O'Brien; Ailís Fagan; Aedín C Culhane; Desmond G Higgins; Michael J Duffy; William M Gallagher
Application of DNA microarray technology in determining breast cancer prognosis and therapeutic response.
Expert opinion on biological therapy 2005;5(8):1069-83.
2005: Louise M Kelly; Yvonne Buggy; Arnold Hill; Norma O'Donovan; Catherine Duggan; Enda W McDermott; Niall J O'Higgins; Leonie Young; Michael J Duffy
Expression of the breast cancer metastasis suppressor gene, BRMS1, in human breast carcinoma: lack of correlation with metastasis to axillary lymph nodes.
Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine 2005;26(4):213-6.
2005: Nicolai Grebenchtchikov; Teresa M Maguire; R Riisbro; Anneke Geurts-Moespot; Norma O'Donovan; Manfred Schmitt; G McGreal; Enda McDermott; N O'Higgins; Nils Brünner; C G J Sweep; Michael J Duffy
Measurement of plasminogen activator system components in plasma and tumor tissue extracts obtained from patients with breast cancer: an EORTC Receptor and Biomarker Group collaboration.
Oncology reports 2005;14(1):235-9.
2005: Neil A O'Brien; Norma O'Donovan; Bríd M Ryan; A D K Hill; Enda McDermott; Niall O'Higgins; Michael J Duffy
Mammaglobin a in breast cancer: existence of multiple molecular forms.
International journal of cancer. Journal international du cancer 2005;114(4):623-7.
2005: Michael J Duffy
Predictive markers in breast and other cancers: a review.
Clinical chemistry 2005;51(3):494-503.
2005: Bríd M Ryan; Norma O'Donovan; Brigid Browne; Caroline O'Shea; John Crown; A D K Hill; Enda McDermott; Niall O'Higgins; Michael J Duffy
Expression of survivin and its splice variants survivin-2B and survivin-DeltaEx3 in breast cancer.
British journal of cancer 2005;92(1):120-4.
2004: Yvonne Buggy; Teresa M Maguire; G McGreal; Enda McDermott; A D K Hill; Niall O'Higgins; Michael J Duffy
Overexpression of the Ets-1 transcription factor in human breast cancer.
British journal of cancer 2004;91(7):1308-15.
2004: Michael J Duffy
Evidence for the clinical use of tumour markers.
Annals of clinical biochemistry 2004;41(Pt 5):370-7.
2004: Michael J Duffy; C Duggan
The urokinase plasminogen activator system: a rich source of tumour markers for the individualised management of patients with cancer.
Clinical biochemistry 2004;37(7):541-8.
2004: A M Troy; Kieran Sheahan; Hugh Mulcahy; Michael J Duffy; J M P Hyland; Diarmuid P O'Donoghue
Expression of Cathepsin B and L antigen and activity is associated with early colorectal cancer progression.
European journal of cancer (Oxford, England : 1990) 2004;40(10):1610-6.
2004: Michael J Duffy; Catherine Duggan; Rachel Keane; A D K Hill; Enda McDermott; John Crown; Niall O'Higgins
High preoperative CA 15-3 concentrations predict adverse outcome in node-negative and node-positive breast cancer: study of 600 patients with histologically confirmed breast cancer.
Clinical chemistry 2004;50(3):559-63.
2004: Michael J Duffy
The urokinase plasminogen activator system: role in malignancy.
Current pharmaceutical design 2004;10(1):39-49.
2003: Caroline O'Shea; Norman McKie; Yvonne Buggy; Catherine Duggan; A D K Hill; Enda McDermott; Niall O'Higgins; Michael J Duffy
Expression of ADAM-9 mRNA and protein in human breast cancer.
International journal of cancer. Journal international du cancer 2003;105(6):754-61.
2003: Michael J Duffy; Arie Van Dalen; C Haglund; L Hansson; R Klapdor; Rolf Lamerz; O Nilsson; C Sturgeon; Ondrej Topolcan
Clinical utility of biochemical markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines.
European journal of cancer (Oxford, England : 1990) 2003;39(6):718-27.
2003: Lisa M Greene; Waleed O Twal; Michael J Duffy; Enda W McDermott; A D K Hill; Niall J O'Higgins; Amanda McCann; Peter A Dervan; Scott Argraves; William M Gallagher
Elevated expression and altered processing of fibulin-1 protein in human breast cancer.
British journal of cancer 2003;88(6):871-8.
2003: Norma O'Donovan; John Crown; Helen Stunell; A D K Hill; Enda McDermott; Niall O'Higgins; Michael J Duffy
Caspase 3 in breast cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(2):738-42.
2002: Neil O'Brien; Teresa M Maguire; Norma O'Donovan; Niamh Lynch; A D K Hill; Enda McDermott; Niall O'Higgins; Michael J Duffy
Mammaglobin a: a promising marker for breast cancer.
Clinical chemistry 2002;48(8):1362-4.
2002: Michael J Duffy
Urokinase plasminogen activator and its inhibitor, PAI-1, as prognostic markers in breast cancer: from pilot to level 1 evidence studies.
Clinical chemistry 2002;48(8):1194-7.
2002: Michael J Duffy
Urokinase-type plasminogen activator: a potent marker of metastatic potential in human cancers.
Biochemical Society transactions 2002;30(2):207-10.
2001: Michael J Duffy
Biochemical markers in breast cancer: which ones are clinically useful?
Clinical biochemistry 2001;34(5):347-52.
2001: Michael J Duffy
Clinical uses of tumor markers: a critical review.
Critical reviews in clinical laboratory sciences 2001;38(3):225-62.
2001: R Cullen; Teresa M Maguire; Enda W McDermott; A D K Hill; Niall J O'Higgins; Michael J Duffy
Studies on oestrogen receptor-alpha and -beta mRNA in breast cancer.
European journal of cancer (Oxford, England : 1990) 2001;37(9):1118-22.
2001: Chris Price; J Allard; G Davies; Anne Dawnay; Michael J Duffy; M France; G Mandarino; Anthony Milford Ward; B Patel; P Sibley; C Sturgeon
Pre- and post-analytical factors that may influence use of serum prostate specific antigen and its isoforms in a screening programme for prostate cancer.
Annals of clinical biochemistry 2001;38(Pt 3):188-216.
2001: Michael J Duffy
Carcinoembryonic antigen as a marker for colorectal cancer: is it clinically useful?
Clinical chemistry 2001;47(4):624-30.
2000: Michael J Duffy; SG Shering; F Sherry; Enda McDermott; Niall O'Higgins
CA 15-3: a prognostic marker in breast cancer.
The International journal of biological markers 2000;15(4):330-3.
2000: roeland hanemaaijer; Jan H Verheijen; Teresa M Maguire; H Visser; Karin H Toet; Enda McDermott; Niall O'Higgins; Michael J Duffy
Increased gelatinase-A and gelatinase-B activities in malignant vs. benign breast tumors.
International journal of cancer. Journal international du cancer 2000;86(2):204-7.
2000: Albert G Remacle; K McCarthy; Agnès Noël; Teresa M Maguire; Enda McDermott; Niall O'Higgins; Jean-Michel Foidart; Michael J Duffy
High levels of TIMP-2 correlate with adverse prognosis in breast cancer.
International journal of cancer. Journal international du cancer 2000;89(2):118-21.
2000: Teresa M Maguire; D Chin; D Soutar; Michael J Duffy
Low levels of urokinase plasminogen activator components in basal cell carcinoma of the skin.
International journal of cancer. Journal international du cancer 2000;85(4):457-9.
2000: Michael J Duffy; Teresa M Maguire; A Hill; Enda McDermott; Niall O'Higgins
Metalloproteinases: role in breast carcinogenesis, invasion and metastasis.
Breast cancer research : BCR 2000;2(4):252-7.
2000: R Cullen; Teresa M Maguire; P Diggin; A Hill; Enda McDermott; Niall O'Higgins; Michael J Duffy
Detection of estrogen receptor-beta mRNA in breast cancer using RT-PCR.
The International journal of biological markers 2000;15(1):114-5.
1999: Michael J Duffy
CA 15-3 and related mucins as circulating markers in breast cancer.
Annals of clinical biochemistry 1999;36 ( Pt 5)():579-86.
1999: Michael J Duffy; Teresa M Maguire; Enda W McDermott; Niall O'Higgins
Urokinase plasminogen activator: a prognostic marker in multiple types of cancer.
Journal of surgical oncology 1999;71(2):130-5.
1999: K McCarthy; Teresa M Maguire; G McGreal; Enda McDermott; Niall O'Higgins; Michael J Duffy
High levels of tissue inhibitor of metalloproteinase-1 predict poor outcome in patients with breast cancer.
International journal of cancer. Journal international du cancer 1999;84(1):44-8.
1998: SG Shering; F Sherry; Enda W McDermott; Niall J O'Higgins; Michael J Duffy
Preoperative CA 15-3 concentrations predict outcome of patients with breast carcinoma.
Cancer 1998;83(12):2521-7.
1998: C G J Sweep; J Geurts-Moespot; N Grebenschikov; JH de Witte; Joop J T M Heuvel; Manfred Schmitt; Michael J Duffy; Fritz Jänicke; Michael D Kramer; John A Foekens; Nils Brünner; G Brugal; A N Pedersen; Th J Benraad
External quality assessment of trans-European multicentre antigen determinations (enzyme-linked immunosorbent assay) of urokinase-type plasminogen activator (uPA) and its type 1 inhibitor (PAI-1) in human breast cancer tissue extracts.
British journal of cancer 1998;78(11):1434-41.
1998: Teresa M Maguire; SG Shering; C M Duggan; E W McDermott; Niall J O'Higgins; Michael J Duffy
High levels of cathepsin B predict poor outcome in patients with breast cancer.
The International journal of biological markers 1998;13(3):139-44.
1998: Michael J Duffy; C Duggan; H E Mulcahy; Enda W McDermott; Niall J O'Higgins
Urokinase plasminogen activator: a prognostic marker in breast cancer including patients with axillary node-negative disease.
Clinical chemistry 1998;44(6 Pt 1):1177-83.
1998: S Kennedy; Michael J Duffy; C Duggan; C Barnes; R Rafferty; Michael D Kramer
Semi-quantitation of urokinase plasminogen activator and its receptor in breast carcinomas by immunocytochemistry.
British journal of cancer 1998;77(10):1638-41.
1998: Michael J Duffy
CA 19-9 as a marker for gastrointestinal cancers: a review.
Annals of clinical biochemistry 1998;35 ( Pt 3)():364-70.
1998: Albert G Remacle; Agnès Noël; C Duggan; Enda McDermott; Niall O'Higgins; Jean-Michel Foidart; Michael J Duffy
Assay of matrix metalloproteinases types 1, 2, 3 and 9 in breast cancer.
British journal of cancer 1998;77(6):926-31.
1997: MM Skelly; A Troy; Michael J Duffy; Hugh Mulcahy; C Duggan; T G Connell; Diarmuid P O'Donoghue; Kieran Sheahan
Urokinase-type plasminogen activator in colorectal cancer: relationship with clinicopathological features and patient outcome.
Clinical cancer research : an official journal of the American Association for Cancer Research 1997;3(10):1837-40.
1997: Teresa M Maguire; SG Shering; Enda W McDermott; Niall O'Higgins; J J Fennelly; J Crown; Michael J Duffy
Assay of E-cadherin by ELISA in human breast cancers.
European journal of cancer (Oxford, England : 1990) 1997;33(3):404-8.
1997: C Duggan; S Kennedy; Michael D Kramer; C Barnes; P Elvin; Enda McDermott; Niall O'Higgins; Michael J Duffy
Plasminogen activator inhibitor type 2 in breast cancer.
British journal of cancer 1997;76(5):622-7.
1996: Marie-Pierre Chenard; L O'Siorain; SG Shering; N Rouyer; Yves Lutz; C Wolf; P Basset; Jean-Pierre Bellocq; Michael J Duffy
High levels of stromelysin-3 correlate with poor prognosis in patients with breast carcinoma.
International journal of cancer. Journal international du cancer 1996;69(6):448-51.
1996: Michael J Duffy
PSA as a marker for prostate cancer: a critical review.
Annals of clinical biochemistry 1996;33 ( Pt 6)():511-9.
1996: Michael J Duffy; C Duggan; Teresa M Maguire; K Mulcahy; P Elvin; Enda McDermott; J J Fennelly; N O'Higgins
Urokinase plasminogen activator as a predictor of aggressive disease in breast cancer.
Enzyme & protein 1996;49(1-3):85-93.
1995: Michael J Duffy
Can molecular markers now be used for early diagnosis of malignancy?
Clinical chemistry 1995;41(10):1410-3.
1995: C Duggan; Teresa M Maguire; Enda McDermott; N O'Higgins; J J Fennelly; Michael J Duffy
Urokinase plasminogen activator and urokinase plasminogen activator receptor in breast cancer.
International journal of cancer. Journal international du cancer 1995;61(5):597-600.
1995: Michael J Duffy; J Blaser; C Duggan; Enda McDermott; N O'Higgins; J J Fennelly; H Tschesche
Assay of matrix metalloproteases types 8 and 9 by ELISA in human breast cancer.
British journal of cancer 1995;71(5):1025-8.
1995: E C Coveney; J G Geraghty; F Sherry; Enda W McDermott; J J Fennelly; N J O'Higgins; Michael J Duffy
The clinical value of CEA and CA 15-3 in breast cancer management.
The International journal of biological markers 1995;10(1):35-41.
1994: Michael J Duffy; D Reilly; Enda W McDermott; N O'Higgins; J J Fennelly; P A Andreasen
Urokinase plasminogen activator as a prognostic marker in different subgroups of patients with breast cancer.
Cancer 1994;74(8):2276-80.
1994: A Nugent; J Gallagher; J Dolan; N O'Higgins; Michael J Duffy
Assay of the c-erbB-2 oncogene encoded protein by ELISA and immunocytochemistry in human breast cancer.
Annals of clinical biochemistry 1994;31 ( Pt 2)():171-3.
1992: J G Geraghty; E C Coveney; F Sherry; N J O'Higgins; Michael J Duffy
CA 15-3 in patients with locoregional and metastatic breast carcinoma.
Cancer 1992;70(12):2831-4.
1992: Michael J Duffy; D Reilly; Jean-Paul Brouillet; Enda W McDermott; C Faul; N O'Higgins; J J Fennelly; Thierry Maudelonde; H Rochefort
Cathepsin D concentration in breast cancer cytosols: correlation with disease-free interval and overall survival.
Clinical chemistry 1992;38(10):2114-6.
1992: A Nugent; Enda W McDermott; K Duffy; N O'Higgins; J J Fennelly; Michael J Duffy
Enzyme-linked immunosorbent assay of c-erbB-2 oncoprotein in breast cancer.
Clinical chemistry 1992;38(8 Pt 1):1471-4.
1992: A Nugent; Enda W McDermott; N O'Higgins; J J Fennelly; Michael J Duffy
Measurement of erbB-2 oncoprotein in human breast cancers by ELISA.
Biochemical Society transactions 1992;20(1):82S.
1991: D Reilly; P Andreasen; Michael J Duffy
Urokinase-type plasminogen activator and its inhibitor PAI-1 in breast cancer: studies at both protein and mRNA level.
Biochemical Society transactions 1991;19(1):44S.
1991: Michael J Duffy; Jean-Paul Brouillet; D Reilly; Enda W McDermott; N O'Higgins; J J Fennelly; Thierry Maudelonde; H Rochefort
Cathepsin D concentration in breast cancer cytosols: correlation with biochemical, histological, and clinical findings.
Clinical chemistry 1991;37(1):101-4.
1990: Michael J Duffy; D Reilly; C O'Sullivan; N O'Higgins; J J Fennelly; P Andreasen
Urokinase-plasminogen activator, a new and independent prognostic marker in breast cancer.
Cancer research 1990;50(21):6827-9.
1990: Michael J Duffy; D Reilly; C O'Sullivan; N O'Higgins; J J Fennelly
Urokinase plasminogen activator and prognosis in breast cancer.
Lancet 1990;335(8681):108.
1989: Michael J Duffy
New cancer markers.
Annals of clinical biochemistry 1989;26 ( Pt 5)():379-87.
1988: Michael J Duffy; P O'Grady; D Devaney; L O'Siorain; J J Fennelly; H J Lijnen
Urokinase-plasminogen activator, a marker for aggressive breast carcinomas. Preliminary report.
Cancer 1988;62(3):531-3.
1988: Michael J Duffy; P O'Grady; D Devaney; L O'Siorain; J J Fennelly; H R Lijnen
Tissue-type plasminogen activator, a new prognostic marker in breast cancer.
Cancer research 1988;48(5):1348-9.
1987: Michael J Duffy
Do proteases play a role in cancer invasion and metastasis?
European journal of cancer & clinical oncology 1987;23(5):583-9.
1986: Michael J Duffy; L O'Siorain; B Waldron; C Smith
Estradiol receptors in human breast carcinomas assayed by use of monoclonal antibodies.
Clinical chemistry 1986;32(10):1972-4.
1985: P O'Grady; H R Lijnen; Michael J Duffy
Multiple forms of plasminogen activator in human breast tumors.
Cancer research 1985;45(12 Pt 1):6216-8.
1984: Michael J Duffy; P O'Grady
Plasminogen activator and cancer.
European journal of cancer & clinical oncology 1984;20(5):577-82.